Scholars Central

Research articlePublished 2016

Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults

Authors: Jennifer A Ohtola, Jessica L Saul-McBeth, Anita S Iyer, David J Leggat, Sadik A Khuder, Noor M Khaskhely, MA Julie Westerink

Journal of AIDS & Clinical Research

Volume 7 · Issue 3 · Pages 1–7

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: The number of aging human immunodeficiency virus-infected (HIV+) individuals living in the United States has substantially grown over the past two decades. Advanced age and HIV infection both increase susceptibility to Streptococcus pneumoniae infection due to B cell dysfunction. The combined impact of these factors on pneumococcal vaccine responses remains unknown. Methods: We assessed serum immunoglobulin (Ig) G and IgM levels and opsonophagocytic killing assay (OPA) titers to pneumococcal serotypes 14 and 23F in HIV+ subjects and HIV-uninfected (HIV–) controls 50-65 years old. HIV+ individuals with CD4+ T cells/μl (CD4) >200 and ≥1 year of antiretroviral therapy (ART) received either a dose of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine 8 weeks later (PCV/PPV) as currently recommended (n=15) or a single dose of PPV only (n=22). HIV– controls received PCV/PPV (n=14). Results: HIV+ PCV/PPV and PPV groups exhibited similar increases in IgG levels and OPA titers for both serotypes after immunization. Postvaccination IgM levels for serotype 23F, but not 14, were significantly higher in HIV+ PCV/PPV compared to PPV groups. IgG and IgM levels for serotype 14 and OPA titers to serotype 23F were significantly reduced in HIV+ compared to HIV- PCV/PPV groups. Serotype-specific IgG levels correlated with OPA titers for all groups. Conclusions: Our data suggest that the recommended PCV/PPV regimen may not significantly improve quantitative or functional antibody responses compared to PPV only in aging HIV+ subjects. Continued efforts aimed at improving vaccine responses in this high risk population are warranted.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of AIDS & Clinical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of AIDS & Clinical Research
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Jennifer A Ohtola”
  • BylineArticles whose byline prints “Jessica L Saul-McBeth”
  • BylineArticles whose byline prints “Anita S Iyer”
  • BylineArticles whose byline prints “David J Leggat”
  • BylineArticles whose byline prints “Sadik A Khuder”
  • BylineArticles whose byline prints “Noor M Khaskhely”
  • BylineArticles whose byline prints “MA Julie Westerink”